Gilead Sciences (GILD) : The money flow analysis of Gilead Sciences (GILD) indicates a $96.75 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $99.4 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.03 and so was the total money flow at $2.64 million. The bulls lapped up $11.05 million worth of block trades on upticks. The money flow was $11.05 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Gilead Sciences (GILD), pushing it down by -0.58% for the day. The stock slid $0.51 and traded at $86.73 during the day. Nonetheless, the stock is 0.07% over the previous weeks close.
Gilead Sciences (GILD) : 14 investment research analysts covering Gilead Sciences (GILD) have an average price target of $115.79 for the near short term. The highest target price given by the Brokerage Firm to the stock is $135 and the lowest target is $97 for the short term. Analysts expect the variance to be within $11.6 of the average price.
Gilead Sciences (NASDAQ:GILD): On Fridays trading session , Opening price of the stock was $87.32 with an intraday high of $87.44. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $86.32. However, the stock managed to close at $86.55, a loss of 0.79% for the day. On the previous day, the stock had closed at $87.24. The total traded volume of the day was 7,374,693 shares.
In a related news, Milligan John F, director officer (President and CEO) of Gilead Sciences Inc, unloaded 112,000 shares at an average price of $84.62 on July 5, 2016. The total amount of the transaction was worth $9,477,440, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.